BIOMAT Database Logo BIOMAT Database Logo

Treatment of cryptorchidism with human chorionic gonadotropin or gonadotropin releasing hormone. A double-blind controlled study of 243 boys. 1988

P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
University Department of Pediatrics, Hvidovre Hospital, Copenhagen, Denmark.

We have conducted a modified double-blind study on the effect of human chorionic gonadotropin (hCG), gonadotropin releasing hormone (GnRH) and placebo on bilateral and unilateral maldescended testes. One hundred and fifty-five boys with bilateral and 88 boys with unilateral cryptorchidism fulfilled the inclusion criteria and completed the treatment protocol. The boys were between 1 and 13 years of age. hCG was administered as intramuscular injections twice weekly for 3 weeks. GnRH and placebo were given intranasally. hCG was superior to GnRH and placebo in the treatment of bilateral maldescended testes (p = 0.0009). Both testes descended in 25% of the boys following treatment with hCG, and improvement in the position of the testes was obtained in a further 25% of the cases. hCG administration resulted in complete testicular descent in 14% of boys with unilateral cryptorchidism compared with 3 and 0% after placebo and GnRH, respectively (p = 0.07). The testis had moved to a more distal position in 46% of the boys treated with hCG. There was no significant difference between the treatment groups with regard to age or initial position of the testes. We conclude that a success rate of 25% justifies the use of hCG in the treatment of maldescended testes, whereas the study did not support a general use of GnRH administered intranasally.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D010906 Pituitary Hormone-Releasing Hormones Peptides, natural or synthetic, that stimulate the release of PITUITARY HORMONES. They were first isolated from the extracts of the HYPOTHALAMUS; MEDIAN EMINENCE; PITUITARY STALK; and NEUROHYPOPHYSIS. In addition, some hypophysiotropic hormones control pituitary cell differentiation, cell proliferation, and hormone synthesis. Some can act on more than one pituitary hormone. Hormones, Pituitary Hormone Releasing,Hypophysiotropic Hormones,Hypothalamic Hypophysiotropic Hormone,Hypothalamic Releasing Factor,Hypothalamic Releasing Hormone,Hypothalamic Releasing Hormones,Hormone, Hypothalamic Hypophysiotropic,Hormones, Hypophysiotropic,Hypophysiotropic Hormone, Hypothalamic,Pituitary Hormone Releasing Hormones,Releasing Hormone, Hypothalamic
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003456 Cryptorchidism A developmental defect in which a TESTIS or both TESTES failed to descend from high in the ABDOMEN to the bottom of the SCROTUM. Testicular descent is essential to normal SPERMATOGENESIS which requires temperature lower than the BODY TEMPERATURE. Cryptorchidism can be subclassified by the location of the maldescended testis. Testis, Undescended,Abdominal Cryptorchidism,Bilateral Cryptorchidism,Cryptorchidism, Unilateral Or Bilateral,Cryptorchism,Inguinal Cryptorchidism,Testes, Undescended,Undescended Testis,Unilateral Cryptorchidism,Cryptorchidism, Abdominal,Cryptorchidism, Bilateral,Cryptorchidism, Inguinal,Cryptorchidism, Unilateral,Undescended Testes
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic

Related Publications

P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone.
February 1986, The New England journal of medicine,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Primary gonadotropin releasing hormone and adjunctive human chorionic gonadotropin treatment in cryptorchidism: a clinical trial.
January 1997, Urology,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial.
December 1987, The Journal of clinical endocrinology and metabolism,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Treatment of cryptorchidism with human chorionic gonadotrophin (hCG) or gonadotrophin releasing hormone (GnRH); reply.
January 1989, Hormone research,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Gonadotropin-releasing hormone (LH-RH) and human chorionic gonadotropin in the treatment of two boys with hypogonadotrophic hypogonadism.
May 1977, Acta paediatrica Scandinavica,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Maintenance of pregnancy in dairy cattle after treatment with human chorionic gonadotropin or gonadotropin-releasing hormone.
August 2008, Journal of dairy science,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Cryptorchidism: treatment with human chorionic gonadotropin--a Venezuelan experience.
January 1997, Archives of andrology,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Treatment of cryptorchidism with pernasal gonadotropin-releasing hormone therapy.
May 1978, Fertility and sterility,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Gonadotropin-Releasing Hormone Agonist Corrects Defective Mini-Puberty in Boys with Cryptorchidism: A Prospective Randomized Study.
January 2018, BioMed research international,
P Christiansen, and J Müller, and S Buhl, and O R Hansen, and N Hobolth, and B B Jacobsen, and P H Jørgensen, and K W Kastrup, and K Nielsen, and L B Nielsen
Treatment of cryptorchidism by intranasal synthetic luteinising-hormone releasing hormone. Results of a collaborative double-blind study.
September 1977, Lancet (London, England),
Copied contents to your clipboard!